In a real-world retrospective study, Luke et al. found that in advanced melanoma, targeted therapy (BRAF/MEK inhibitors) achieved a median OS of 33.1 months, while OS was not reached for immunotherapy (nivolumab or pembrolizumab), indicating prolonged survival [17]. This evidence concerns the gene MAP2K7 and melanoma.